Novo Nordisk acquires Korean approval of ‘Saxenda,’ GLP-1 analogue obesity treatment

Novo Nordisk Korea(President Rana Azfar Zafar) announced that Saxenda(generic name: liraglutide), its new obesity therapy, was approved from the Ministry of Food and Drug Safety on the 21^st.

Saxenda is the world’s obesity therapy approved as GLP-1(Glucagon-Like Peptide 1) analogue.

According to the company, GLP-1, a human hormone secreted from food ingestion, reduces hungriness by delivering ...